Disciplined Growth Investors Inc Myriad Genetics Inc Transaction History

Disciplined Growth Investors Inc

  • $5.44 Billion
  • Q1 2024

A detailed history of Disciplined Growth Investors Inc transactions in Myriad Genetics Inc stock. As of the latest transaction made, Disciplined Growth Investors Inc holds 2,077,293 shares of MYGN stock, worth $50.8 Million. This represents 0.81% of its overall portfolio holdings.

Number of Shares
2,077,293
Previous 1,955,236 6.24%
Holding current value
$50.8 Million
Previous $37.4 Million 18.34%
% of portfolio
0.81%
Previous 0.82%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
BUY
$17.59 - $23.59 $2.15 Million - $2.88 Million
122,057 Added 6.24%
2,077,293 $44.3 Million
Q4 2023

Feb 14, 2024
SELL
$13.91 - $21.32 $251,437 - $385,380
-18,076 Reduced 0.92%
1,955,236 $37.4 Million
Q3 2023

Nov 14, 2023
SELL
$15.99 - $23.22 $583,475 - $847,297
-36,490 Reduced 1.82%
1,973,312 $31.7 Million
Q2 2023

Aug 14, 2023
SELL
$17.56 - $23.76 $1.39 Million - $1.88 Million
-78,982 Reduced 3.78%
2,009,802 $46.6 Million
Q1 2023

May 15, 2023
SELL
$15.26 - $23.75 $2.8 Million - $4.36 Million
-183,660 Reduced 8.08%
2,088,784 $48.5 Million
Q4 2022

Feb 14, 2023
SELL
$14.51 - $20.99 $87,727 - $126,905
-6,046 Reduced 0.27%
2,272,444 $33 Million
Q3 2022

Nov 15, 2022
BUY
$18.21 - $27.88 $6.88 Million - $10.5 Million
377,703 Added 19.87%
2,278,490 $43.5 Million
Q2 2022

Aug 15, 2022
BUY
$16.45 - $25.88 $432,783 - $680,876
26,309 Added 1.4%
1,900,787 $34.5 Million
Q1 2022

May 16, 2022
BUY
$22.67 - $28.01 $634,487 - $783,943
27,988 Added 1.52%
1,874,478 $47.2 Million
Q4 2021

Feb 14, 2022
SELL
$24.13 - $32.63 $930,018 - $1.26 Million
-38,542 Reduced 2.04%
1,846,490 $51 Million
Q3 2021

Nov 15, 2021
BUY
$29.97 - $36.66 $186,143 - $227,695
6,211 Added 0.33%
1,885,032 $60.9 Million
Q2 2021

Aug 16, 2021
BUY
$25.39 - $32.61 $1.29 Million - $1.65 Million
50,690 Added 2.77%
1,878,821 $57.5 Million
Q1 2021

May 17, 2021
SELL
$19.92 - $31.6 $4.98 Million - $7.9 Million
-249,944 Reduced 12.03%
1,828,131 $55.7 Million
Q4 2020

Feb 16, 2021
SELL
$12.16 - $19.77 $678,552 - $1.1 Million
-55,802 Reduced 2.62%
2,078,075 $41.1 Million
Q3 2020

Nov 16, 2020
SELL
$11.25 - $14.75 $678,678 - $889,823
-60,327 Reduced 2.75%
2,133,877 $27.8 Million
Q2 2020

Aug 14, 2020
SELL
$10.69 - $16.49 $8.93 Million - $13.8 Million
-835,141 Reduced 27.57%
2,194,204 $24.9 Million
Q1 2020

May 15, 2020
BUY
$9.78 - $29.53 $1.68 Million - $5.06 Million
171,330 Added 5.99%
3,029,345 $43.4 Million
Q4 2019

Feb 14, 2020
BUY
$20.93 - $35.1 $1.59 Million - $2.67 Million
75,988 Added 2.73%
2,858,015 $77.8 Million
Q3 2019

Nov 15, 2019
BUY
$22.08 - $47.08 $1.65 Million - $3.52 Million
74,663 Added 2.76%
2,782,027 $79.6 Million
Q2 2019

Aug 14, 2019
SELL
$22.67 - $35.0 $3.28 Million - $5.06 Million
-144,700 Reduced 5.07%
2,707,364 $75.2 Million
Q1 2019

May 14, 2019
BUY
$26.93 - $34.7 $40.7 Million - $52.5 Million
1,511,931 Added 112.82%
2,852,064 $94.7 Million
Q4 2018

Feb 13, 2019
SELL
$27.23 - $45.56 $468,846 - $784,452
-17,218 Reduced 1.27%
1,340,133 $39 Million
Q3 2018

Nov 16, 2018
BUY
$37.57 - $50.34 $2.1 Million - $2.81 Million
55,826 Added 4.29%
1,357,351 $62.4 Million
Q2 2018

Aug 15, 2018
SELL
$27.75 - $40.17 $545,176 - $789,179
-19,646 Reduced 1.49%
1,301,525 $48.6 Million
Q1 2018

May 17, 2018
SELL
$28.83 - $41.01 $768,521 - $1.09 Million
-26,657 Reduced 1.98%
1,321,171 $39 Million
Q4 2017

Feb 15, 2018
SELL
$28.45 - $37.14 $7,937 - $10,362
-279 Reduced 0.02%
1,347,828 $46.3 Million
Q3 2017

Nov 14, 2017
BUY
$24.01 - $36.2 $32.4 Million - $48.8 Million
1,348,107
1,348,107 $48.8 Million

Others Institutions Holding MYGN

# of Institutions
191
Shares Held
94.2M
Call Options Held
280K
Put Options Held
14.3K
View Full List

About MYRIAD GENETICS INC

MYGN Quotes by TradingView
  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.97B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Disciplined Growth Investors Inc Portfolio

Follow Disciplined Growth Investors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Disciplined Growth Investors Inc , based on Form 13F filings with the SEC.

News

Stay updated on Disciplined Growth Investors Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email